99 related articles for article (PubMed ID: 10796590)
21. A randomized trial to assess safety and immunogenicity of alternative formulations of a quadrivalent meningococcal (A, C, Y, and W-135) tetanus protein conjugate vaccine in toddlers.
McVernon J; Nolan T; Richmond P; Reynolds G; Nissen M; Lambert SB; Marshall H; Papa T; Rehm C
Pediatr Infect Dis J; 2012 Jan; 31(1):e15-23. PubMed ID: 22094636
[TBL] [Abstract][Full Text] [Related]
22. Serogroup B meningococcal vaccines.
Zimmer SM; Stephens DS
Curr Opin Investig Drugs; 2006 Aug; 7(8):733-9. PubMed ID: 16955685
[TBL] [Abstract][Full Text] [Related]
23. Emergence of serogroup X meningococcal disease in Africa: need for a vaccine.
Xie O; Pollard AJ; Mueller JE; Norheim G
Vaccine; 2013 Jun; 31(27):2852-61. PubMed ID: 23623866
[TBL] [Abstract][Full Text] [Related]
24. [Paediatric meningococcal meningitis in France: ACTIV/GPIP network results].
Levy C; Taha MK; Bingen E; Cohen R;
Arch Pediatr; 2012 Sep; 19 Suppl 2():S49-54. PubMed ID: 22883366
[TBL] [Abstract][Full Text] [Related]
25. Meningococcal vaccine in travelers.
Wilder-Smith A
Curr Opin Infect Dis; 2007 Oct; 20(5):454-60. PubMed ID: 17762777
[TBL] [Abstract][Full Text] [Related]
26. Meningococcal serogroup C immunogenicity, antibody persistence and memory B-cells induced by the monovalent meningococcal serogroup C versus quadrivalent meningococcal serogroup ACWY conjugate booster vaccine: A randomized controlled trial.
van Ravenhorst MB; van der Klis FRM; van Rooijen DM; Knol MJ; Stoof SP; Sanders EAM; Berbers GAM
Vaccine; 2017 Aug; 35(36):4745-4752. PubMed ID: 28668575
[TBL] [Abstract][Full Text] [Related]
27. Early clinical experience with a candidate meningococcal B recombinant vaccine (rMenB) in healthy adults.
Toneatto D; Oster P; deBoer AC; Emerson A; Santos GF; Ypma E; DeTora L; Pizza M; Kimura A; Dull P
Hum Vaccin; 2011 Jul; 7(7):781-91. PubMed ID: 21734467
[TBL] [Abstract][Full Text] [Related]
28. Bordetella pertussis fimbriae are effective carrier proteins in Neisseria meningitidis serogroup C conjugate vaccines.
Reddin KM; Crowley-Luke A; Clark SO; Vincent PJ; Gorringe AR; Hudson MJ; Robinson A
FEMS Immunol Med Microbiol; 2001 Aug; 31(2):153-62. PubMed ID: 11549423
[TBL] [Abstract][Full Text] [Related]
29. The Diversity of Meningococcal Carriage Across the African Meningitis Belt and the Impact of Vaccination With a Group A Meningococcal Conjugate Vaccine.
MenAfriCar consortium
J Infect Dis; 2015 Oct; 212(8):1298-307. PubMed ID: 25858956
[TBL] [Abstract][Full Text] [Related]
30. Long-term protection in children with meningococcal C conjugate vaccination: lessons learned.
Borrow R; Miller E
Expert Rev Vaccines; 2006 Dec; 5(6):851-7. PubMed ID: 17184222
[TBL] [Abstract][Full Text] [Related]
31. Conjugate vaccines for preventing Haemophilus influenzae type b infections.
Swingler G; Fransman D; Hussey G
Cochrane Database Syst Rev; 2003; (4):CD001729. PubMed ID: 14583937
[TBL] [Abstract][Full Text] [Related]
32. Trends and variations in the epidemiology of meningococcal disease in Kuwait 1987-2013.
Husain EH; Barakat M; Al-Saleh M
J Infect Public Health; 2015; 8(5):441-7. PubMed ID: 25779346
[TBL] [Abstract][Full Text] [Related]
33. Development of new vaccines against meningococcal disease.
Bröker M
Arzneimittelforschung; 2003; 53(12):805-13. PubMed ID: 14732960
[TBL] [Abstract][Full Text] [Related]
34. Antibody persistence after serogroup C meningococcal conjugate immunization of United Kingdom primary-school children in 1999-2000 and response to a booster: a phase 4 clinical trial.
Perrett KP; Winter AP; Kibwana E; Jin C; John TM; Yu LM; Borrow R; Curtis N; Pollard AJ
Clin Infect Dis; 2010 Jun; 50(12):1601-10. PubMed ID: 20459323
[TBL] [Abstract][Full Text] [Related]
35. Single priming dose of meningococcal group C conjugate vaccine (NeisVac-C®) in infants.
Poellabauer EM; Pavlova BG; Fritsch S; Singer J; Neubauer C; Doralt J; Valenta-Singer B; Ehrlich HJ
Vaccine; 2013 Aug; 31(35):3611-6. PubMed ID: 23672977
[TBL] [Abstract][Full Text] [Related]
36. Update on the use of meningococcal serogroup C CRM₁₉₇-conjugate vaccine (Meningitec) against meningitis.
Badahdah AM; Rashid H; Khatami A
Expert Rev Vaccines; 2016; 15(1):9-29. PubMed ID: 26560735
[TBL] [Abstract][Full Text] [Related]
37. Meningococcal vaccines.
Collins CL; Pollard AJ
Curr Opin Investig Drugs; 2002 Jul; 3(7):975-9. PubMed ID: 12186274
[TBL] [Abstract][Full Text] [Related]
38. Meningococcal serogroup B-specific responses after vaccination with bivalent rLP2086: 4 year follow-up of a randomised, single-blind, placebo-controlled, phase 2 trial.
Marshall HS; Richmond PC; Beeslaar J; Jiang Q; Jansen KU; Garcés-Sánchez M; Martinón-Torres F; Szenborn L; Wysocki J; Eiden J; Harris SL; Jones TR; Lee SS; Perez JL;
Lancet Infect Dis; 2017 Jan; 17(1):58-67. PubMed ID: 27745812
[TBL] [Abstract][Full Text] [Related]
39. Safety and immunogenicity of a serogroups A/C Neisseria meningitidis oligosaccharide-protein conjugate vaccine in young children. A randomized controlled trial.
Lieberman JM; Chiu SS; Wong VK; Partidge S; Chang SJ; Chiu CY; Gheesling LL; Carlone GM; Ward JI
JAMA; 1996 May; 275(19):1499-503. PubMed ID: 8622225
[TBL] [Abstract][Full Text] [Related]
40. Antibody persistence and booster response of a quadrivalent meningococcal conjugate vaccine in adolescents.
Baxter R; Reisinger K; Block SL; Izu A; Odrljin T; Dull P
J Pediatr; 2014 Jun; 164(6):1409-15.e4. PubMed ID: 24657122
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
